Inactive Instrument

Spotlight Innovation Inc.

Equities

STLT

US8492071050

Biotechnology & Medical Research

Celtic Biotech Iowa, Inc. Enters into an Exclusive License Agreement with Celtic Biotech Limited

March 15, 2014 at 12:19 am IST

On March 10, 2014 Celtic Biotech Iowa, Inc. entered into an exclusive license agreement with Celtic Biotech Limited. Celtic Iowa was granted the exclusive worldwide rights for a period of five years to exploit a patent relating to Crotoxin Administration.

Latest news about Spotlight Innovation Inc.

Spotlight Innovation Inc. Announces Management Changes	11/18/11	CI
Spotlight Innovation Enters into Research Agreement with Indiana University	18/17/18	CI
Spotlight Innovation Inc. Enters into Sponsored Research Agreement with The Brigham and Women's Hospital Inc	27/17/27	CI
Spotlight Innovation Inc. announced that it has received $0.4 million in funding	31/17/31	CI
Spotlight Innovation Inc. Announces Management Changes	23/17/23	CI
Spotlight Innovation Licenses Additional Anti-Zika Virus Compounds	15/17/15	CI
Spotlight Innovation Inc. Enters into a Second Exclusive License Agreement with Florida State University Research Foundation	01/17/01	CI
Spotlight Innovation Inc. Announces Executive Changes	05/17/05	CI
Spotlight Innovation Inc. announced that it has received $0.17 million in funding from K4 Enterprises, LLC	30/16/30	CI
Spotlight Innovation Inc. announced that it has received $0.83 million in funding from K4 Enterprises, LLC	16/16/16	CI
Spotlight Innovation Inc. Appoints Chitra Edwin as Senior Vice President of Regulatory Affairs and Compliance	08/16/08	CI
Spotlight Innovation Announces Formation of Scientific Advisory Board	06/16/06	CI
Spotlight Innovation Announces Strategic Investment in Solx, Inc	30/16/30	CI
SOLX, Inc. announced that it has received $0.8 million in funding from Spotlight Innovation Inc.	30/16/30	CI
Spotlight Innovation Inc. Enters into Exclusive License Agreement with Florida State University Research Foundation	11/16/11	CI
Spotlight Innovation Announces Appointment to Scientific Advisory Board	20/16/20	CI
Spotlight Innovation Inc. Enters into License Agreement with Indiana University Research and Technology Corporation	17/16/17	CI
Spotlight Innovation Inc. Establishes Subsidiary as Caretta Therapeutics	06/16/06	CI
Spotlight Innovation Inc. Enters into Sponsored Research Agreement with Florida State University	26/16/26	CI
Spotlight Innovation Appoints Cassandra K. MacArthur as Senior Vice President of Regulatory Affairs and Compliance	01/16/01	CI
Spotlight Innovation Inc. announced that it expects to receive $2.5 million in funding	31/16/31	CI
Spotlight Innovation Inc. Appoints Geoffrey Laff as Vice President of Scientific Strategy	14/16/14	CI
Spotlight Innovation Inc. Announces Board Resignations	16/16/16	CI
Spotlight Innovation Inc. Enters into an Agreement with Maitland Labs to Establish its Drug Production and Product Development Facilities	10/16/10	CI
Spotlight Innovation Inc. announced that it has received $0.85 million in funding	31/16/31	CI

Chart Spotlight Innovation Inc.

Duration

Period

More charts

Company Profile

Spotlight Innovation Inc. is a pharmaceutical company. The Company is focused on acquiring the intellectual property rights to therapeutics designed to address unmet medical needs. As of June 30, 2017, the Company had four subsidiaries: Celtic Biotech Iowa, Inc. (Celtic Iowa), Caretta Therapeutics, LLC (Caretta), SMA Therapeutics, LLC (SMA), and Zika Therapeutics, LLC (Zika). It is focused on various diseases, including cancer, pain management, Zika Virus infection and spinal muscular atrophy. The Company, through Celtic Iowa, holds interest in Celtic Biotech Limited, which is engaged in developing specialized compounds derived from snake venom, for the treatment of solid cancers and cancer imaging. The Company, through Caretta, is focused on developing the commercialization of over-the-counter products. It is also engaged in discovery, synthetic modification, and preclinical validation of drug-like compounds intended to treat patients with Zika virus infection.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.57B
ARGENX SE	+3.23%	22.82B
GENMAB A/S	-10.44%	18.19B
WUXI APPTEC CO., LTD.	-41.74%	16.54B
BEIGENE, LTD.	-13.31%	16.5B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.39B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.1B

Bio Therapeutic Drugs